Search Results

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Taysha Gene Therapies, Inc. announced that, on June 3, 2024, the Compensation Committee of Taysha’s Board of Directors granted three new employees, in the aggregate, options to purchase 360,000 shares of the Company’s common stock in connection with their employment.

Taysha Gene Therapies, Inc. announced that it has commenced an underwritten public offering of up to $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies together.